Pfizer Inc. (PFE) Wednesday announced the FDA approval of its supplemental Biologics License Application or sBLA for ADCETRIS otherwise known as brentuximab vedotin combined with lenalidomide and a rituximab product.
This treatment is for adults with relapsed or refractory large B-cell lymphoma or LBCL, including diffuse large B-cell lymphoma or DLBCL and high-grade B-cell lymphoma or HGBL, after at least two prior systemic therapies. It is specifically for patients ineligible for autologous stem cell transplantation or auto-HSCT or CAR T-cell therapy.
The FDA approval is supported by Phase 3 ECHELON-3 study data, which showed a significant improvement in overall survival or OS for relapsed/refractory DLBCL patients treated with ADCETRIS plus lenalidomide and rituximab. The study included heavily pre-treated patients, including those previously treated with CAR-T therapy, and demonstrated a survival benefit regardless of CD30 expression.
LBCL, a type of NHL, affects B lymphocytes, key immune cells. DLBCL is its most common and aggressive form, with over 25,000 U.S. cases yearly. Up to 40% relapse or become refractory, and 3,500+ need third-line therapy. Despite advances like bispecifics or CAR-T, a high unmet need remains.
PFE is currently trading at $25.58 or 0.18% higher on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.